Protagenic Therapeutics, Inc. (PTIX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.76

From 52W high−76.71%

Volume1201.00

Market cap$1.39M

P/E (TTM)0.3x

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.76

From 52W high

−76.71%

Volume

1201.00

Market cap

$1.39M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

0.3x

RSI (14)

46.8

MomentumView details →

1D Return

−1.64%

YTD Return

−41.35%

SummaryUpdated Jun 1, 2026

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) is a clinical-stage biopharmaceutical company founded to develop novel therapeutics for stress-related neuropsychiatric and mood disorders. The company went public in April 2021 and is headquartered in New York, New York. Protagenic is currently focused on advancing its lead compound PT00114 through clinical trials, representing a potentially breakthrough approach to treating conditions like depression, anxiety, PTSD, and drug addiction through a novel neurobiological mechanism.

Ask drillr about Protagenic Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.3x

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

316.93%

ROA (TTM)

261.82%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

+100.00%

EPS YoY

+165.56%

FCF YoY

+20.17%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

+52.83%

MomentumView details →

1D Return

−1.64%

YTD Return

−41.35%

1Y Return

−76.25%

RSI (14)

46.8

vs 50D SMA

−2.39%

vs 200D SMA

+34.80%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

0.66x

Quick Ratio

0.66x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

88.17%

Beats (12Q)

1/12

Next Q EPS Est

−$4.48

Avg Surprise (4Q)

88.17%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

5.46M

Op. CF (TTM)

−2.58M

Next earningsNov 17, 2026 →

Latest newsMore news →

Protagenic Therapeutics received written responses from the U.S. Food and Drug Administration to its Type B pre-IND meeting request for PT00114, with the FDA raising no objection to the planned Phase 1 program design, dose-escalation approach, and CMC and nonclinical packages.61d ago

Similar companies

Iterum Therapeutics plcITRM Avenue Therapeutics, Inc.ATXI Abpro CorporationABP Artelo Biosciences, Inc.ARTL Hepion Pharmaceuticals, Inc.HEPA Biodexa Pharmaceuticals PlcBDRX Find similar companies →

Latest newsMore news →